251. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens
- Author
-
Francesca Gatti, Loredana Sarmati, Emanuele Nicastri, Giorgio Palù, Vincenzo Vullo, Gabriella d'Ettorre, Massimo Andreoni, Caterina Boldrin, Saverio Giuseppe Parisi, Luca Dori, Marco Montano, Carolina Andreoni, and Anna Rita Buonomini
- Subjects
Adult ,Male ,HIV-DNA ,Settore MED/17 - Malattie Infettive ,HIV Infections ,Cohort Studies ,Proviruses ,Antiretroviral Therapy, Highly Active ,Virology ,Immunopathology ,Humans ,Protease inhibitor (pharmacology) ,Prospective Studies ,Prospective cohort study ,Sida ,Adverse effect ,biology ,HIV Protease Inhibitors ,Middle Aged ,biology.organism_classification ,HIV infection ,CD4 Lymphocyte Count ,Regimen ,Infectious Diseases ,DNA, Viral ,Lentivirus ,Simplification therapy ,HIV-1 ,Female ,Viral disease - Abstract
Simplified regimens containing protease-inhibitors (PI)-sparing combinations were used in patients with virological suppression after prolonged highly active antiretroviral therapy. This study evaluated the total HIV-1 DNA quantitation as a predictor of long-term success for PI-sparing simplified therapy. Sixty-two patients were enrolled in a prospective non-randomized cohort. All patients have been receiving a triple-therapy regimen, two nucleoside reverse transcriptase inhibitors (NRTIs) plus one PI, for at least 9 months and were characterized by undetectable plasma HIV-1 RNA levels (
- Published
- 2007